Back

Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial

26 August 2018 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Cardiac patients with comorbidities Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Jochen Seufert

University of Freiburg, Freiburg (Germany)

5 More presentations in this session

Presentation thumbnail
Professor S. Verma (Toronto, CA)
Abstract Slides
Presentation thumbnail
Professor S. Bain (Swansea, GB)
Abstract Slides
Presentation thumbnail
Professor C. Lang (Dundee, GB)
Abstract
Presentation thumbnail
Ms M. Panahi (London, GB)
Abstract Slides
Presentation thumbnail
Professor S. Martsevich (Moscow, RU)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 3 - Cardiac patients with comorbidities

The Event

Event poster

ESC Congress 2018

26 August 2018 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial
7 April 2022
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
6 November 2025
thumbnail
Congress Presentation
Effects of glucagon like peptide 1 receptor agonist initiation in patients with heart failure and reduced ejection fraction and implantable cardiac devices
19 May 2025
thumbnail
Congress Presentation
Efficacy and safety of semaglutide in patients with obesity-related heart failure: a meta-analysis of randomized clinical trials
3 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources